Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen
Recruiting now
Conditions studied: Liver Transplant Infection
In brief
Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic/pharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.
Key facts
- Study ID
- NCT06718517
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- People needed
- 65
- Starts
- 2024-08-28
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2024-12-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- adult OLT recipients (age ≥ 18 years);
- documented Gram-negative infections occurring in the first 90 days after transplantation;
- treatment with beta-lactam based-regimens;
- signed informed consent.
You may not qualify if…
- patients receiving beta-lactam-based regimens for less than 48 hours;
- patients with isolation of a Gram-negative resistant to all available beta-lactam classes;
- patients on palliative care and/or not resuscitation order.
Where it is running
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.